Update on prostate-specific antigen (PSA)-based screening

Prostate-specific Antigen (psa) Screening – Current Views

Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.

BACKGROUND Prostate cancer (PC) is the most commonly diagnosed non-cutaneous cancer in men and their second or third leading cause of cancer death. Prostate-specific antigen (PSA) testing for PC has been in common practice for more than 20 years. OBJECTIVES A systematic review of the scientific literature was conducted to determine the effectiveness of PSA-based population screening programs ...

Prostate-Specific Antigen (PSA) Test

• Prostate-specific antigen (PSA) is a protein produced by cells of the prostate gland. The PSA test measures the level of PSA in the blood (see Question 1). • The U.S. Food and Drug Administration (FDA) has approved the use of the PSA test along with a digital rectal exam to help detect prostate cancer in men age 50 and older. The FDA has also approved the PSA test to monitor patients with a h...

PSA Screening in Prostate Cancer

Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...

Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.

BACKGROUND The prostate-specific antigen (PSA) blood test has become widely used in Canada to test for prostate cancer (PC), the most common cancer among Canadian men. Data suggest that population-based PSA screening may not improve overall survival. OBJECTIVES This analysis aimed to review existing economic evaluations of population-based PSA screening, determine current spending on opportun...